Neutralising antibodies to certolizumab pegol do not appear to impact on efficacy or safety in patients with crohn's disease

被引：0
|
作者：
Nesbitt, A. M. [1 ]
Stephens, S. [2 ]
Bloomfield, R. [3 ]
机构：
[1] UCB, Antibody Biol Div, Slough, Berks, England
[2] UCB, Clin Assay Dept, Slough, Berks, England
[3] UCB, Slough, Berks, England
来源：
GUT | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
372
引用
收藏
页码：A142 / A142
页数：1
相关论文
共 50 条
  • [21] Certolizumab Pegol for Active Crohn's Disease
    Blackmore, Laura J.
    Harris, Adam W.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (03) : 327 - 327
  • [22] Certolizumab pegol for the treatment of Crohn's disease
    Baker, Danial E.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (06) : 683 - 691
  • [23] Efficacy and safety of certolizumab pegol in Crohn's disease patients with loss of response or intolerance to previous anti-TNF
    Ferrer Bradley, I.
    Marin, I.
    Maroto, N.
    Mora, M.
    Hinojosa, E.
    Lopez, B.
    Menchen, L.
    Hinojosa, J.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S276 - S276
  • [24] Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
    Wade, Janet R.
    Parker, Gerry
    Kosutic, Gordana
    Feagen, Brian G.
    Sandborn, William J.
    Laveille, Christian
    Oliver, Ruth
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 866 - 874
  • [25] Assessment of the Efficacy of Certolizumab Pegol in the Maintenance of Response for the Treatment of Crohn's Disease
    Lee, Scott D.
    Ko, Cynthia W.
    Wahbeh, Ghassan
    Cullinan, Cory
    Etter, Scott
    Sinanan, Mika N.
    Wheat, Chelle
    GASTROENTEROLOGY, 2011, 140 (05) : S282 - S282
  • [26] Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease
    Tun, Gloria S. Z.
    Lobo, Alan J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (02) : 317 - 327
  • [27] Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease
    Niels Vande Casteele
    Diane R. Mould
    Jason Coarse
    Iram Hasan
    Ann Gils
    Brian Feagan
    William J. Sandborn
    Clinical Pharmacokinetics, 2017, 56 : 1513 - 1523
  • [28] Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease
    Vande Casteele, Niels
    Mould, Diane R.
    Coarse, Jason
    Hasan, Iram
    Gils, Ann
    Feagan, Brian
    Sandborn, William J.
    CLINICAL PHARMACOKINETICS, 2017, 56 (12) : 1513 - 1523
  • [29] Certolizumab Pegol for the Management of Crohn's Disease in Adults
    Rivkin, Anastasia
    CLINICAL THERAPEUTICS, 2009, 31 (06) : 1158 - 1176
  • [30] Pharmakokinetics of Certolizumab Pegol Induction in Crohn's Disease
    Wolf, Douglas C.
    Wolf, Christine
    GASTROENTEROLOGY, 2015, 148 (04) : S867 - S868
12345